Details for New Drug Application (NDA): 216874

NDA 216874 describes PACLITAXEL, which is a drug marketed by Accord Hlthcare, Actavis Totowa, Alembic, Dash Pharms, Fresenius Kabi Usa, Gland, Hikma, Hospira, MSN, Pharmobedient, Pliva Lachema, Sandoz, Teva Pharms, Teva Pharms Usa, Am Regent, Cipla, Hengrui Pharma, Mylan, Shuangcheng, and Teva Pharms Inc, and is included in twenty-two NDAs. It is available from seventeen suppliers. Additional details are available on the PACLITAXEL profile page.

The generic ingredient in PACLITAXEL is paclitaxel. There are sixty-nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the paclitaxel profile page.

Summary for 216874

Tradename:	PACLITAXEL
Applicant:	Alembic
Ingredient:	paclitaxel
Patents:	0

Pharmacology for NDA: 216874

Physiological Effect

Microtubule Inhibition

Medical Subject Heading (MeSH) Categories for 216874

Antineoplastic Agents, Phytogenic

Tubulin Modulators

Suppliers and Packaging for NDA: 216874

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874	ANDA	Alembic Pharmaceuticals Limited	46708-620	46708-620-05	1 VIAL, MULTI-DOSE in 1 CARTON (46708-620-05) / 5 mL in 1 VIAL, MULTI-DOSE
PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	216874	ANDA	Alembic Pharmaceuticals Limited	46708-621	46708-621-17	1 VIAL, MULTI-DOSE in 1 CARTON (46708-621-17) / 16.7 mL in 1 VIAL, MULTI-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INJECTION			Strength	6MG/ML
Approval Date:	Oct 20, 2022	TE:	AP	RLD:	No

Complete Access Available with Subscription